Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2025-05-22 00:00:00 ET · period of report 2025-05-20 · accession 0001415889-25-014186 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-22 | 2025-05-20 | SPRY | Fitzpatrick Alexander A | CLO | M - OptEx | $5.58 | +100.0K | 192.6K | +108% | +$558.0K |
| D | 2025-05-22 | 2025-05-20 | SPRY | Fitzpatrick Alexander A | CLO | S - Sale+OE | $14.10 | -103.0K | 89.6K | -53% | -$1.45M |
| D | 2025-05-22 | 2025-05-20 | SPRY | Fitzpatrick Alexander A | CLO | M - OptEx | $0.00 | -100.0K | 200.0K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-20 | M | A | 100,000 | $5.58 | 192,582 | D | — | — | (F1) Includes 3,355 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024. |
| 2 | Common | Common Stock | 2025-05-20 | S | D | 102,969 | $14.10 | 89,613 | D | — | — | (F2) The weighted average sale price for the transaction reported was $14.0966 and the range of prices were between $14.02 and $14.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-05-20 | M | D | 100,000 | $0.00 | 200,000 | D | $5.58 · — to 2034-01-01 | 100,000 Common Stock | (F3) 25% of the shares subject to the option vested on January 1, 2025, and the remaining shares will vest monthly thereafter over three years. |